Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline

Abstract Background Hypercalcemia of malignancy (HCM) is the most common metabolic complication of malignancies, but its incidence may be declining due to potent chemotherapeutic agents. The high mortality associated with HCM has declined markedly due to the introduction of increasingly effective ch...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of clinical endocrinology and metabolism 2023-03, Vol.108 (3), p.507-528
Hauptverfasser:	El-Hajj Fuleihan, Ghada, Clines, Gregory A, Hu, Mimi I, Marcocci, Claudio, Murad, M Hassan, Piggott, Thomas, Van Poznak, Catherine, Wu, Joy Y, Drake, Matthew T
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adults Antineoplastic drugs Bone Density Conservation Agents - therapeutic use Calcitonin Calcitriol Canada Cancer Chemotherapy Corticosteroids Denosumab Diphosphonates - therapeutic use Disodium pamidronate Drug therapy Humans Hypercalcemia Hypercalcemia - drug therapy Hypercalcemia - etiology Literature reviews Malignancy Medical research Medicine, Experimental Mortality Neoplasms - complications Neuroendocrine tumors Patients
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!